Kaempferol is a flavonoid that has been extensively investigated owing to its antitumor effects. Nevertheless, little is known about its underlying mechanisms of action. We aimed to explore the role of kaempferol in breast cancer (BC), and thus we investigated how kaempferol suppresses
the growth of BC cells. The cells were treated with kaempferol, and the effects on multiple cancer-associated pathways were evaluated. The MTS assay was used to study the cell growth inhibition induced by kaempferol. The cell cycle was analyzed by flow cytometry. Western blotting was used
to analyze cellular apoptosis and DNA damage. We found that the proliferation of the triple-negative BC (TNBC) MDA-MB-231 cells was suppressed effectively by kaempferol. Interestingly, the suppressive effect of kaempferol on cell proliferation was stronger in MDA-MB-231 cells than in the estrogen
receptor-positive BT474 cell line. Furthermore, after the treatment with kaempferol for 48 h, the population of cells in the G1 phase was significantly reduced, from 85.48% to 51.35%, and the population of cells in the G2 phase increased markedly from 9.27% to 37.5%,
which indicated that kaempferol contributed to the induction of G2/M arrest. Kaempferol also induced apoptosis and DNA damage in MDA-MB-231 cells. Kaempferol increased the expression levels of γH2AX, cleaved caspase 9, cleaved caspase 3, and p-ATM compared to those of the
control group. Collectively, these results showed that kaempferol may be a potential drug for the effective treatment of TNBC.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics
Keywords:
Apoptosis;
Breast cancer (BC);
Cell cycle;
Cell proliferation;
DNA damage;
Kaempferol
Document Type: Research Article
Affiliations:
1:
Department of Medical Laboratory, Shanghai Second People’s Hospital, Shanghai, P.R. China
2:
Madonna University, Livonia, MI, USA
Publication date:
21 June 2019
This article was made available online on 03 April 2018 as a Fast Track article with title: "Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis, and DNA damage in breast cancer cells".
More about this publication?
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.